IL267540B - Glyceryl 3-hydroxybutyrates for migraine symptom management - Google Patents

Glyceryl 3-hydroxybutyrates for migraine symptom management

Info

Publication number
IL267540B
IL267540B IL267540A IL26754019A IL267540B IL 267540 B IL267540 B IL 267540B IL 267540 A IL267540 A IL 267540A IL 26754019 A IL26754019 A IL 26754019A IL 267540 B IL267540 B IL 267540B
Authority
IL
Israel
Prior art keywords
hydroxybutyrate
glyceryl
migraine
compound
tris
Prior art date
Application number
IL267540A
Other languages
English (en)
Hebrew (he)
Other versions
IL267540A (en
Inventor
Sami Hashim
Original Assignee
Neuroenergy Ventures Inc
Sami Hashim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroenergy Ventures Inc, Sami Hashim filed Critical Neuroenergy Ventures Inc
Publication of IL267540A publication Critical patent/IL267540A/en
Publication of IL267540B publication Critical patent/IL267540B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL267540A 2016-12-23 2017-11-30 Glyceryl 3-hydroxybutyrates for migraine symptom management IL267540B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/389,828 US20180177753A1 (en) 2016-12-23 2016-12-23 Glyceryl 3-hydroxybutyrates for migraine symptom management
PCT/US2017/063832 WO2018118369A1 (en) 2016-12-23 2017-11-30 Glyceryl 3-hydroxybutyrates for migraine symptom management

Publications (2)

Publication Number Publication Date
IL267540A IL267540A (en) 2019-08-29
IL267540B true IL267540B (en) 2022-07-01

Family

ID=62624821

Family Applications (1)

Application Number Title Priority Date Filing Date
IL267540A IL267540B (en) 2016-12-23 2017-11-30 Glyceryl 3-hydroxybutyrates for migraine symptom management

Country Status (13)

Country Link
US (2) US20180177753A1 (cg-RX-API-DMAC7.html)
EP (1) EP3558458B1 (cg-RX-API-DMAC7.html)
JP (1) JP7108320B2 (cg-RX-API-DMAC7.html)
KR (1) KR102390608B1 (cg-RX-API-DMAC7.html)
CN (1) CN110167637B (cg-RX-API-DMAC7.html)
BR (1) BR112019012431A2 (cg-RX-API-DMAC7.html)
CA (1) CA3046350C (cg-RX-API-DMAC7.html)
ES (1) ES2962879T3 (cg-RX-API-DMAC7.html)
IL (1) IL267540B (cg-RX-API-DMAC7.html)
MX (1) MX389468B (cg-RX-API-DMAC7.html)
MY (1) MY190308A (cg-RX-API-DMAC7.html)
PT (1) PT3558458T (cg-RX-API-DMAC7.html)
WO (1) WO2018118369A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
EP3558280B1 (en) 2016-12-21 2023-06-07 Universitäts-kinderspital Beider Basel Migraine prevention and treatment
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
BR112021014012A2 (pt) * 2019-01-17 2021-09-21 Ioi Oleo Gmbh Processo para a produção de lipídeos que contêm unidades estruturais com base em glicerídeos de ácidos hidroxicarboxílicos
ES2941943T3 (es) * 2019-01-17 2023-05-26 Ketolipix Therapeutics Gmbh Método para la producción de glicéridos de ácidos hidroxicarboxílicos
BR112021017954A2 (pt) 2019-03-14 2021-11-16 Neuroenergy Ventures Inc Formulação de mascaramento de sabor para compostos de corpo cetônico
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
PL3976021T3 (pl) * 2019-05-30 2025-07-21 Neuroenergy Ventures, Inc. Tri(beta-hydroksymaślan) glicerolu do zastosowania w leczeniu i zapobieganiu przemijającym atakom niedokrwiennym neuronów
CN114008014B (zh) * 2019-06-12 2024-03-22 凯托利皮克斯治疗有限责任公司 用于生产酰基封端的3-羟基羧酸的多元醇基酯的方法
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
IT201900018488A1 (it) * 2019-10-10 2021-04-10 Dr Schaer S P A Procedimento di preparazione del tris-(3-idrossibutirrato)-gliceril estere
IT201900018491A1 (it) * 2019-10-10 2021-04-10 Dr Schaer S P A Procedimento di purificazione del tris-(3-idrossibutirrato)-gliceril estere
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
MX2024005533A (es) 2021-11-12 2024-07-29 Arxada Ag Compuestos derivados de polioles.
US20250002446A1 (en) * 2021-11-26 2025-01-02 Arxada Ag Acetoacetate Based Ketals
US12023382B2 (en) 2022-01-18 2024-07-02 Today Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
US20240299548A1 (en) * 2022-01-18 2024-09-12 Today, Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
WO2024083889A1 (en) 2022-10-18 2024-04-25 Arxada Ag Polyol-derived compounds
WO2025074001A2 (en) 2023-10-05 2025-04-10 Arxada Ag Enzymatic reduction of acetoacetate
WO2025196156A1 (en) 2024-03-20 2025-09-25 Arxada Ag Continuous hydrogenation process of acetoacetate esters
WO2025224319A1 (en) 2024-04-25 2025-10-30 Arxada Ag Reduction of acetoacetate esters in the presence of amines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124589B2 (en) 2000-05-01 2012-02-28 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
GB0420856D0 (en) 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
US7807718B2 (en) * 2006-06-30 2010-10-05 Sami A. Hashim Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
WO2010084356A1 (en) * 2009-01-24 2010-07-29 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
CA2873057C (en) 2011-05-09 2020-02-25 University Of South Florida The use of ketone esters for prevention of cns oxygen toxicity
US20140072654A1 (en) 2011-12-23 2014-03-13 Savind, Inc. Cancer with metabolic therapy and hyperbaric oxygen
FR2997302B1 (fr) * 2012-10-29 2015-02-06 Assist Publ Hopitaux De Paris Prevention et traitement des deficits en pyruvate deshydrogenase
EP2914251B1 (en) 2012-11-05 2019-08-21 The United States of America, as represented by The Secretary, Department of Health and Human Services Ketone bodies to protect tissues from damage by ionizing radiation
WO2014085652A1 (en) 2012-11-28 2014-06-05 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
KR102499654B1 (ko) * 2013-03-19 2023-02-13 유니버시티 오브 사우스 플로리다 상승되고 지속되는 케톤증을 생성하기 위한 조성물 및 방법
GB201314127D0 (en) 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
WO2015156865A1 (en) 2014-01-13 2015-10-15 University Of South Florida Methods of sustaining dietary ketosis and its effects on lipid profile
US20160078782A1 (en) * 2014-09-17 2016-03-17 The Trustees Of Boston College Glucose Ketone Index for MetabolicTherapy
US9364456B1 (en) 2015-06-30 2016-06-14 University Of South Florida Ketone esters for treatment of angelman syndrome
US20180200220A1 (en) 2015-07-10 2018-07-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10376482B2 (en) 2016-04-03 2019-08-13 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
CA3021784A1 (en) 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
WO2018009208A1 (en) 2016-07-08 2018-01-11 Cognate Nutritionals, Inc. Nutritional mitiggation of the cns effects of traumatic brain injury
CN109890381A (zh) 2016-09-12 2019-06-14 南佛罗里达大学 酮改善神经再生
EP3558280B1 (en) 2016-12-21 2023-06-07 Universitäts-kinderspital Beider Basel Migraine prevention and treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DI LORENZO C ET AL., MIGRAINE IMPROVEMENT DURING SHORT LASTING KETOGENESIS: A PROOF-OF-CONCEPT STUDY, 25 August 2014 (2014-08-25) *
HASHIM S ET AL., KETONE BODY THERAPY: FROM THE KETOGENIC DIET TO THE ORAL ADMINISTRATION OF KETONE ESTER, 5 March 2014 (2014-03-05) *

Also Published As

Publication number Publication date
MX389468B (es) 2025-03-20
CN110167637B (zh) 2023-03-14
JP7108320B2 (ja) 2022-07-28
IL267540A (en) 2019-08-29
US10792269B2 (en) 2020-10-06
EP3558458A4 (en) 2020-08-12
PT3558458T (pt) 2023-11-27
US20190117612A1 (en) 2019-04-25
MX2019006844A (es) 2019-08-16
CA3046350C (en) 2022-08-16
EP3558458B1 (en) 2023-10-18
CN110167637A (zh) 2019-08-23
JP2020502250A (ja) 2020-01-23
WO2018118369A1 (en) 2018-06-28
ES2962879T3 (es) 2024-03-21
CA3046350A1 (en) 2018-06-28
BR112019012431A2 (pt) 2020-04-14
KR102390608B1 (ko) 2022-04-25
EP3558458A1 (en) 2019-10-30
KR20190099465A (ko) 2019-08-27
MY190308A (en) 2022-04-13
US20180177753A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
IL267540B (en) Glyceryl 3-hydroxybutyrates for migraine symptom management
US11638702B2 (en) Glyceryl 3-hydroxybutyrates for traumatic brain injury
KR101503970B1 (ko) 오메가-3 풍부화된 비경구 영양 수중-어유 에멀전
WO2008143642A2 (en) Methods of treating and preventing ocular neovascularization with omega-3 polyunsaturated fatty acids
EP3664628B1 (en) Methods and compositions relating to emulsions comprising fish oil and/or omega-3 fatty acids
Sabinari et al. Influence of lipid class used for omega-3 fatty acid supplementation on liver fat accumulation in MASLD
JP7608707B2 (ja) 近視進行抑制剤、機能性食品及び眼科用組成物
CN103648494A (zh) 在降低氧化应激中的dha和epa
Miyoshi et al. Oral tributyrin prevents endotoxin-induced lipid metabolism disorder
CN118678891A (zh) 与脂肪酸缺乏的治疗和预防有关的方法和组合物
HK40012930A (en) Glyceryl 3-hydroxybutyrates for migraine symptom management
HK40012930B (en) Glyceryl 3-hydroxybutyrates for migraine symptom management
JPH06271464A (ja) 消化器系障害の予防または治療用アラキドン酸含有組成物
US20200009099A1 (en) Compositions and methods for the prevention and/or treatment of schistosomiasis
Kłęk et al. The use of intravenous emulsions containing omega-3 unsaturated fatty acids in clinical practice: recommendations of a team of experts
Ballesteros-Pomar et al. Nutrition in lipidemias Topic 22
RU2019139669A (ru) САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ
EP1147769A2 (de) Verwendung von mehrfach ungesättigten Fettsäuren, insbesondere Omega-3-Fettsäuren, zur Behandlung von Enuresis und Inkontinenz
Poudel-Tandukar et al. ROLE OF EICOSAPENTAENOIC ACID IN MENTAL HEALTH
HK40023767B (en) Methods and compositions relating to emulsions comprising fish oil and/or omega-3 fatty acids